Bosutinib‐associated interstitial lung disease and pleural effusion: A case report and literature review

Bosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.

Detalles Bibliográficos
Autores principales: Liu, Qiuying (Selina), Ass'ad, Nour Ali, Arana Yi, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145267/
https://www.ncbi.nlm.nih.gov/pubmed/34094551
http://dx.doi.org/10.1002/ccr3.3164
Descripción
Sumario:Bosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.

Ejemplares similares